Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.
Bicycle Therapeutics, a UK-based developer of treatments for diseases with a high unmet need spun out of research institute MRC Laboratory of Molecular Biology, floated on the Nasdaq Global Market yesterday following a $60.7m initial public offering.
The company issued approximately 4.3 million American Depositary Shares, equivalent to the same number of ordinary shares, priced at $14. Shares dropped to $12 by the end of close yesterday.
Bicycle had initially hoped to raise as much as $86m through…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
